Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Levonordefrin is the (–)-enantiomer of nordefrin, a synthetic derivative of norepinephrine (Item No. 16673), that acts as a vasoconstrictor.1 Levonordefrin (1-5 µg/kg) rapidly increases blood pressure and heart rate in anesthetized dogs and has a more potent effect on blood pressure than the dextronordefrin enantiomer.2 It also inhibits carbamylcholine-induced uterine contractions in isolated rat uterine strips (EC50 = 0.0032 µg/ml). Levonordefrin (0.514 and 1.542 mg/kg), in combination with mepivacaine (Item No. 23402) and administered via intraoral infiltration, increases systolic arterial blood pressure in anesthetized dogs, however, the effect is not dose-dependent and the increase is not greater than 5.33%.3 Formulations containing levonordefrin have been used in combination with local anesthetics in dentistry to prolong anesthetic effects.
WARNING This product is not for human or veterinary use.
1. Vasoconstrictors: Chemistry, mode of action, and dosage. Anesthesia and Analgesia in Dermatologic Surgery 42, 29-60 (2008).
2. Some pharmacologic properties of levo-
3. Cardiovascular alterations caused by the administration of 2% mepivacaine HCl with 1:20,000 levonordefrin (Carbocain®) in dogs. Braz. Dent. J. 8(2), 85-90 (1997).